COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis.
A549 Cells
Angiotensin-Converting Enzyme 2
Animals
Anti-Inflammatory Agents
/ therapeutic use
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
Antiviral Agents
/ therapeutic use
Betacoronavirus
/ drug effects
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
COVID-19
Cell Line
Chlorocebus aethiops
Coronavirus Infections
/ diagnosis
Humans
Immunization, Passive
/ methods
Lymphocyte Count
Pandemics
/ prevention & control
Peptidyl-Dipeptidase A
/ metabolism
Pneumonia, Viral
/ diagnosis
SARS-CoV-2
Spike Glycoprotein, Coronavirus
/ metabolism
Vero Cells
SARS-CoV2 infection
immune system
outbreak
prevention
treatment
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
21 Jul 2020
21 Jul 2020
Historique:
received:
01
06
2020
revised:
16
07
2020
accepted:
17
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
4
8
2020
Statut:
epublish
Résumé
Coronavirus 2 (CoV) Severe Acute Respiratory Syndrome (SARS-CoV2) is causing a highly infectious pandemic pneumonia. Coronaviruses are positive sense single-stranded RNA viruses that infect several animal species, causing symptoms that range from those similar to the common cold to severe respiratory syndrome. The Angiotensin Converting Enzyme 2 (ACE2) is the SARS-CoV2 functional receptor. Measures are currently undertaken worldwide to control the infection to avoid disruption of the social and economic equilibrium, especially in countries with poor healthcare resources. In a guarded optimistic view, we hope that the undertaken preventive and treatment measures will at least contribute to contain viral diffusion, attenuate activity, or even eliminate SARS-CoV2. In this review, we discuss emerging perspectives for prevention/treatment of COVID-19 infection. In addition to vaccines under development, passive immunization is an open opportunity since patients develop neutralizing antibodies. A full spectrum of potential drugs for COVID-19 infections could in turn affect virus binding or enzymatic activities involved in viral replication and transcription. Furthermore, clinical trials are currently evaluating the safety and efficacy of anti-inflammatory drugs, such as tocilizumab. Bioinformatics may allow characterization of specific CD8+ and CD4+ T cell responses; thus, CoV2 T cells' frequency can be correlated with the disease severity and outcome. Combinatorial antibody phage display may be empowered to identify the immune repertoire of CoV2-specific neutralizing antibodies.
Identifiants
pubmed: 32708112
pii: ijms21145145
doi: 10.3390/ijms21145145
pmc: PMC7404132
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Antiviral Agents
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Peptidyl-Dipeptidase A
EC 3.4.15.1
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Front Immunol. 2018 Dec 21;9:3004
pubmed: 30622532
Clin Chem Lab Med. 2020 Jun 25;58(7):1131-1134
pubmed: 32119647
Cell Res. 2013 Feb;23(2):300-2
pubmed: 23208422
Emerg Microbes Infect. 2018 Mar 21;7(1):41
pubmed: 29568066
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 16;43(0):E014
pubmed: 32061198
Cell Biosci. 2020 Mar 16;10:40
pubmed: 32190290
Diabetes Metab Res Rev. 2011 Mar;27(3):216-29
pubmed: 21309048
Emerg Infect Dis. 2005 Jul;11(7):1016-20
pubmed: 16022774
J Virol. 2013 Jul;87(14):8017-28
pubmed: 23678171
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
EMBO J. 1994 May 1;13(9):2236-43
pubmed: 7514533
J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670
pubmed: 32196083
Int Immunopharmacol. 2020 Aug;85:106688
pubmed: 32544867
Lancet. 2020 May 30;395(10238):1695-1704
pubmed: 32401715
Emerg Microbes Infect. 2020 Dec;9(1):727-732
pubmed: 32196410
J Med Virol. 2020 Apr 15;:
pubmed: 32293713
Emerg Microbes Infect. 2020 Dec;9(1):275-277
pubmed: 32005086
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
Emerg Microbes Infect. 2020 Dec;9(1):221-236
pubmed: 31987001
J Exp Med. 2005 Dec 5;202(11):1575-85
pubmed: 16330816
Emerg Microbes Infect. 2019;8(1):516-530
pubmed: 30938227
Front Immunol. 2019 Dec 03;10:2776
pubmed: 31849959
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Nature. 2008 Dec 4;456(7222):658-62
pubmed: 18820679
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
EMBO J. 1998 Nov 2;17(21):6230-40
pubmed: 9799232
Asian Pac J Allergy Immunol. 2020 Mar;38(1):10-18
pubmed: 32134278
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
Am J Hematol. 2013 Dec;88(12):1035-40
pubmed: 23907744
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Nat Rev Microbiol. 2009 Mar;7(3):226-36
pubmed: 19198616
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
Science. 2020 Jul 3;369(6499):77-81
pubmed: 32376603
Front Immunol. 2020 May 15;11:1061
pubmed: 32574262
J Appl Lab Med. 2020 May 19;:
pubmed: 32428207
Emerg Microbes Infect. 2020 Dec;9(1):542-544
pubmed: 32148172
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Biosci Trends. 2020 Mar 16;14(1):69-71
pubmed: 31996494
Chin J Integr Med. 2020 Apr;26(4):243-250
pubmed: 32065348
Biochem Biophys Res Commun. 2003 Dec 26;312(4):1159-64
pubmed: 14651994
Nat Rev Rheumatol. 2020 Mar;16(3):155-166
pubmed: 32034323
Nature. 2020 Jul 30;:
pubmed: 32731258
Chest. 2020 Jul;158(1):e9-e13
pubmed: 32243945
PLoS Negl Trop Dis. 2017 Dec 21;11(12):e0006000
pubmed: 29267278
Nat Rev Drug Discov. 2020 Mar;19(3):149-150
pubmed: 32127666
Science. 2020 Jan 31;367(6477):492-493
pubmed: 32001631
Cell. 2020 Aug 6;182(3):685-712.e19
pubmed: 32645325
Immunology. 2020 Jul;160(3):223-232
pubmed: 32460358
JAMA. 2020 Mar 27;:
pubmed: 32219428
J Biol Chem. 2016 Apr 22;291(17):9218-32
pubmed: 26953343
Sci Adv. 2019 Apr 10;5(4):eaav4580
pubmed: 30989115
JAMA. 2020 Feb 7;:
pubmed: 32031570
Nat Rev Microbiol. 2013 Dec;11(12):836-48
pubmed: 24217413
Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2
pubmed: 32183941
Expert Opin Ther Pat. 2013 Oct;23(10):1337-48
pubmed: 23905913
Curr Opin Anaesthesiol. 2015 Apr;28(2):227-36
pubmed: 25590467
Chembiochem. 2020 Mar 2;21(5):730-738
pubmed: 32022370
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Mol Cell Probes. 2002 Jun;16(3):223-9
pubmed: 12144774
Nat Commun. 2020 May 20;11(1):2601
pubmed: 32433465
JAMA. 2020 Jun 3;:
pubmed: 32492084
J Rheumatol. 1997 Jan;24(1):55-60
pubmed: 9002011
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Am J Pathol. 2020 Aug;190(8):1680-1690
pubmed: 32473109
Trials. 2020 Jun 8;21(1):499
pubmed: 32513308
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Crit Care. 2020 Mar 16;24(1):91
pubmed: 32178711
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Autoimmun Rev. 2020 Jul;19(7):102554
pubmed: 32380316
Int J Antimicrob Agents. 2020 Apr;55(4):105944
pubmed: 32179150
Drug Des Devel Ther. 2018 Dec 19;13:57-70
pubmed: 30587928
Hum Vaccin Immunother. 2020 Jun 2;16(6):1232-1238
pubmed: 32186952
N Engl J Med. 2020 May 7;382(19):1851-1852
pubmed: 32187463
Clin Chem Lab Med. 2020 Jun 25;58(7):1063-1069
pubmed: 32191623
Microbiol Spectr. 2014 Dec;2(6):
pubmed: 26104444
Intern Emerg Med. 2020 Aug;15(5):819-824
pubmed: 32468508
Int J Antimicrob Agents. 2016 Oct;48(4):349-52
pubmed: 27546219
Biochem Biophys Res Commun. 2020 Feb 17;:
pubmed: 32081428
J Immunol. 2015 May 1;194(9):4089-93
pubmed: 25821216
J Med Virol. 2020 May;92(5):495-500
pubmed: 32022276
Nature. 2004 Apr 1;428(6982):561-4
pubmed: 15024391
Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120
pubmed: 32172226
Methods Mol Biol. 2015;1282:1-23
pubmed: 25720466
JAMA. 2020 Mar 11;:
pubmed: 32159775
Drug Discov Today. 2020 Apr;25(4):668-688
pubmed: 32006468
Diagnostics (Basel). 2020 Mar 18;10(3):
pubmed: 32197339